Why the study?
Do genetic variants in SLC28A3 and UGT1A6 predict anthracycline-induced cardiotoxicity in children?
Do genetic variants in SLC28A3 and UGT1A6 predict anthracycline-induced cardiotoxicity in children?
A prediction model combining genetic variants in SLC28A3 and UGT1A6 with clinical risk factors may help identify pediatric patients at high risk for anthracycline-induced cardiotoxicity.
Answers are grounded in this paper and cite their sources.
May support risk stratification for pediatric anthracycline recipients; extends observational validation but requires prospective trials before practice change.
. We validated genetic variants in two genes predictive of ACT in an independent cohort. A prediction model combining replicated genetic variants as well as clinical risk factors might be able to identify high- and low-risk patients who could benefit from alternative treatment options.
No takes yet. Share an insight, caveat, or question.
Visscher et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: